Special Issue

Immunomodulatory Potential of Essential Oils and Their Compounds

Message from the Guest Editors

The use of natural chemical compounds, including essential oils (Eos) and their compounds (EOCs), to fight pathogens has been increasingly successful, and work on their implementation into treatment has accelerated significantly over the past decade. They have been used for hundreds of years as an alternative form of treatment against infections. It is worth noting that these compounds have almost no side effects, and if any occur, they are mild. Scientific advances, including the development of fields such as pharmacognosy, biochemistry, physiology, enable us to thoroughly understand the mechanism of action of phytotherapeutics. In this Special Issue, we will publish laboratory studies and reviews on the immunostimulatory potential of essential oils and their compounds. Potential topics include in vitro/ex vivo evaluation of innate and/or acquired immune responses in the presence of (1) EOs and/or EOCs, (2) EOs or EOCs and bacterial antigens, and (3) bacteria pre-treated with EOs or EOCs.

- immunomodulatory activity
- immune response
- immune cells
- natural compounds
- essential oils
- essential oil compounds
- cytokines
- chemokines
- gene expression

Guest Editors

Dr. Paweł Kwiatkowski

Department of Diagnostic Immunology, Chair of Microbiology, Immunology and Laboratory Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland

Dr. Monika Sienkiewicz

Department of Pharmaceutical Microbiology and Microbiological Diagnostics, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/154018

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).